2-aminoindane HCl
2-aminoindane HCl structure
|
Common Name | 2-aminoindane HCl | ||
|---|---|---|---|---|
| CAS Number | 2338-18-3 | Molecular Weight | 169.651 | |
| Density | 1.056g/cm3 | Boiling Point | 226.2ºC at 760mmHg | |
| Molecular Formula | C9H12ClN | Melting Point | 245-247 °C(lit.) | |
| MSDS | Chinese USA | Flash Point | 96.8ºC | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Central cyanosis on a psychiatric unit treated at the Salford Royal Hospital.
Thorax 69(12) , 1157-8, (2014) We describe a case of acquired methaemoglobinaemia due to frequent use of the 'legal high' known as 'Pink Panthers'. This contains 5,6-Methylenedioxy-2-aminoindane and 2-Aminoindane, both amphetamine analogues with the potential to cause methaemoglobinaemia. ... |
|
|
Oxygen-18 studies on the oxidative deamination mechanism of alicyclic primary amines in rabbit liver microsomes.
Arch. Biochem. Biophys. 215(2) , 433-43, (1982)
|
|
|
Assessment of a potential dopaminergic prodrug moiety in several ring systems.
J. Med. Chem. 29(10) , 2016-20, (1986) The ortho hydroxy/methyl, hydroxy/hydroxymethyl, hydroxy/formyl, and hydroxy/carboxy substitution patterns, some of which confer dopaminergic agonist effects upon 2-aminotetralin ring systems, have been incorporated into beta-phenethylamine, 2-aminoindan, and... |
|
|
Synthesis, dopaminergic profile, and molecular dynamics calculations of N-aralkyl substituted 2-aminoindans.
Bioorg. Med. Chem. 16(6) , 3233-44, (2008) Brain dopaminergic system has a crucial role in the etiology of several neuropsychiatric disorders, including Parkinson's disease, depression, and schizophrenia. Several dopaminergic drugs are used to treat these pathologies, but many problems are attributed ... |
|
|
Dopaminergic structure-activity relationships of 2-aminoindans and cardiovascular action and dopaminergic activity of 4-hydroxy, 5-methyl, 2-di-n-propylaminoindan (RD-211).
J. Pharmacol. Exp. Ther. 256(2) , 751-6, (1991) Dopaminergic structure-activity relationships of 2-aminoindans were evaluated for their ability to inhibit responses to stimulation of cardioaccelerator nerves in cats. The major observations were as follows: 1) Unsubstituted di-n-propyl- and diethyl 2-aminoi... |
|
|
N-aralkyl substitution of 2-aminoindans. Synthesis and their inotropic and chronotropic activity in isolated guinea pig atria.
Arzneimittelforschung 47(11) , 1208-10, (1997) Amino substitution of rigid forms of dopamine 4,5-dihydroxy-2-aminoindan and 5,6-dihydroxy-2-aminoindan with aralkyl functionalities were carried out to investigate the role of such structural modifications upon cardiac inotropic-chronotropic activity. Compou... |
|
|
Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity.
J. Med. Chem. 34(10) , 3125-32, (1991) In an effort to determine the effect of side chain conformational restriction on opioid receptor selectivity, the cyclic phenylalanine analogues 2-aminoindan-2-carboxylic acid (Aic), 2-aminotetralin-2-carboxylic acid (Atc), and tetrahydroisoquinoline-3-carbox... |
|
|
The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline.
J. Neurochem. 112(5) , 1131-7, (2010) The anti-parkinsonian drug, rasagiline [N-propargyl-1-(R)-aminoindan; Azilect(R)], is a secondary cyclic benzylamine and indane derivative, which provides irreversible, potent monoamine oxidase-B (MAO-B) inhibition and possesses neuroprotective and neuroresto... |
|
|
Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro.
BMC Pharmacol. 11 , 2, (2011) Rasagiline, a new drug developed to treat Parkinson's disease, is known to inhibit monoamine oxidase B. However, its metabolite R-(-)-aminoindan does not show this kind of activity. The present series of in vitro experiments using the rat hippocampal slice pr... |
|
|
Conformationally restricted congeners of dopamine derived from 2-aminoindan.
J. Med. Chem. 25(12) , 1442-6, (1982) Two series of N-substituted 2-aminoindan systems have been prepared: 4,5-dihydroxy-2-aminoindan (1) has a hydroxylation pattern analogous to the alpha conformer of dopamine, and 5,6-dihydroxy-2-aminoindan (2) has a hydroxylation pattern of the beta conformer ... |